Kazakhstan Medical Device Registration: Applicant Eligibility and Authorized Representative Requirements

1. Key takeaways

The applicant for national registration of a medical device in Kazakhstan may be the manufacturer itself or an entity duly authorized by the manufacturer. However, a foreign manufacturer cannot close the compliance loop directly as a foreign entity. A legal entity registered in Kazakhstan must act as the authorized representative, handling registration matters on the basis of a legalized power of attorney issued by the manufacturer. The registration certificate holder and the authorized representative are two distinct roles: the certificate holder is usually the manufacturer, while the authorized representative carries the in-country liaison duties and post-market obligations. Only one authorized representative may be designated for a single medical device, and this is the hardest constraint in the Kazakhstan compliance architecture. Any distribution strategy must be built around this rule, because the representative named on the certificate controls the lawful pathway to the market. In practice this means that market entry planning, distributor selection and registration budgeting all converge on the same question: who will stand in Kazakhstan as the representative of record. Companies that answer this question early avoid the most common source of delay, which is a defective authorization file discovered only at formal screening.

2. Legal basis

3. Expert insights

Insight one: separation of the certificate holder and the authorized representative is the standard structure in Kazakhstan. The manufacturer acts as the holder of the registration certificate, sometimes described as the manager, while the law requires a Kazakhstan-based entity to take over adverse event monitoring and post-market activities. The advantage of this separation is that a change of representative does not automatically affect the manufacturer’s holder status; the disadvantage is that the manufacturer’s room for maneuver is limited when the representative fails to cooperate. For budgeting purposes, the practical estimate is that representative services are priced separately from registration fees and recur annually, so they belong in the recurring layer of the cost model rather than the one-off layer. Practical estimate: plan the relationship contractually from day one.

Insight two: the power of attorney must be legalized, and this is the document where formal defects occur most often. A power of attorney issued by a foreign manufacturer must pass a legalization procedure, such as consular certification or notarization, before it can be used. If the document does not meet formal requirements, the dossier will be returned at the formal screening stage, and the time cost of that stage is entirely avoidable with proper preparation. Legalization typically means consular certification or, where an applicable treaty provides, an apostille, and the internal signing chain of the manufacturer should be mapped before the document is drafted, because a signature from the wrong office invalidates the whole file.

Insight three: the representative may be a distributor, a representative office or a third party, but liability is not reduced by status. The law imposes no restriction on who may act as the representative: a distributor, a representative office or an independent third party all qualify. Whatever the status, the obligations are statutory and are not lightened on the grounds that the party was merely helping to submit documents. When selecting a representative, assess its capacity to carry statutory responsibilities, including compliance staffing, vigilance systems and response resources. In practice, distributors frequently offer representation as a bundled service, but bundling should not obscure the fact that the statutory duties sit with the named entity alone, whatever the commercial arrangement behind it.

Insight four: one device, one representative is a key bargaining chip in commercial negotiations. Because the representative is named on the registration certificate, the original representative must cooperate when the manufacturer switches channels. This constraint puts the representative in a strong negotiating position. GRZAN recommends writing cooperation obligations and exit mechanisms into the appointment agreement, balancing the relationship through contract rather than through informal understanding. Manufacturers that anticipate channel changes should therefore negotiate data handover, certificate cooperation and non-blocking clauses at the outset, while their leverage is still intact.

Insight five: the Union pathway is more flexible on representation. Under the Union pathway, a foreign manufacturer must appoint an authorized representative located in Kazakhstan or in another EAEU member state. Companies intending to cover several markets can therefore plan their representative network together with the Union pathway, instead of treating each country separately. The choice between the national pathway and the Union pathway should be revisited whenever the product portfolio or the list of target markets changes, because representation requirements differ between the two routes.

4. Practical recommendations

1. Before issuing the power of attorney, confirm the legalization requirements, whether consular certification or notarization, to avoid a formal rejection.
2. State the cooperation obligations, change procedure and exit mechanism of the representative in the appointment agreement, and agree on liability for breach.
3. When selecting a representative, assess its capacity to carry statutory responsibilities, including the compliance team, the vigilance system and response resources.
4. Companies with multi-country EAEU plans should consider the representative network and the Union pathway together.
5. When the contact details or address of the representative change, file a dossier change without delay.

5. Verification checklist

• □ Applicant eligibility has been confirmed, whether the manufacturer itself or a duly authorized entity
• □ The power of attorney has completed the legalization procedure, whether certification or notarization
• □ The authorized representative is a legal entity registered in Kazakhstan
• □ Only one authorized representative has been designated for the device
• □ The appointment agreement contains cooperation obligations, a change procedure and an exit mechanism
• □ A dossier update process for changes of representative contact details and address has been established

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support in Kazakhstan for medical device manufacturers, importers and authorized representatives, covering eligibility review, dossier preparation, representative appointment and post-market compliance. Engagements typically begin with an eligibility and documentation gap assessment, followed by a structured appointment package. For inquiries, contact info@grzanglobal.com.